{"doi":"10.3390/dj10120232","title":"Oral Side Effects in Patients with Metastatic Renal Cell Carcinoma Receiving the Antiangiogenic Agent Pazopanib—Report of Three Cases","abstract":"<jats:p>Pazopanib is a potent multi-kinase inhibitor that hinders angiogenesis and blocks tumor growth. It has been approved for the treatment of metastatic renal cell carcinoma (mRCC) and advanced soft tissue sarcoma. There is emerging evidence that bleeding is a common adverse effect of pazopanib and other targeted therapies in patients with mRCC. In addition, jaw osteonecrosis related to pazopanib was recently described in the literature. We report three cases of patients with mRCC who developed adverse oral events related to pazopanib. The first patient, treated with pazopanib as monotherapy, presented with gingival bleeding and oral burning sensation. The other two patients receiving pazopanib as monotherapy and pazopanib followed by sunitinib, respectively, presented complaining about mandibular pain; a diagnosis of medication-related osteonecrosis of the jaw (MRONJ) was rendered in both cases. Gingival bleeding and MRONJ may develop as oral side effects of pazopanib use. The cases presented here aim to alert and inform health care professionals about the risk of adverse oral events in patients with mRCC receiving the antiangiogenic agent pazopanib.</jats:p>","journal":"Dentistry Journal","year":2022,"id":600293,"datarank":0.3453877639491069,"base_score":2.302585092994046,"endowment":2.302585092994046,"self_citation_contribution":0.3453877639491069,"citation_network_contribution":0.0,"self_endowment_contribution":0.3453877639491069,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1538930,"name":"Emmanouil Vardas","orcid":null,"position":1,"is_corresponding":false},{"id":1538931,"name":"Styliani Tziveleka","orcid":null,"position":2,"is_corresponding":false},{"id":1538933,"name":"Maria Georgaki","orcid":null,"position":3,"is_corresponding":false},{"id":1538934,"name":"Maria Kouri","orcid":"0000-0002-0009-4911","position":4,"is_corresponding":false},{"id":1538936,"name":"Konstantinos Katoumas","orcid":null,"position":5,"is_corresponding":false},{"id":1538937,"name":"Evangelia Piperi","orcid":"0000-0001-5389-1837","position":6,"is_corresponding":false},{"id":1538938,"name":"Nikolaos Nikitakis","orcid":null,"position":7,"is_corresponding":false},{"id":1538929,"name":"Erofili Papadopoulou","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Oral Side Effects in Patients with Metastatic Renal Cell Carcinoma Receiving the Antiangiogenic Agent Pazopanib—Report of Three Cases","abstract":"<jats:p>Pazopanib is a potent multi-kinase inhibitor that hinders angiogenesis and blocks tumor growth. It has been approved for the treatment of metastatic renal cell carcinoma (mRCC) and advanced soft tissue sarcoma. There is emerging evidence that bleeding is a common adverse effect of pazopanib and other targeted therapies in patients with mRCC. In addition, jaw osteonecrosis related to pazopanib was recently described in the literature. We report three cases of patients with mRCC who developed adverse oral events related to pazopanib. The first patient, treated with pazopanib as monotherapy, presented with gingival bleeding and oral burning sensation. The other two patients receiving pazopanib as monotherapy and pazopanib followed by sunitinib, respectively, presented complaining about mandibular pain; a diagnosis of medication-related osteonecrosis of the jaw (MRONJ) was rendered in both cases. Gingival bleeding and MRONJ may develop as oral side effects of pazopanib use. The cases presented here aim to alert and inform health care professionals about the risk of adverse oral events in patients with mRCC receiving the antiangiogenic agent pazopanib.</jats:p>","is_dataset_classified":null,"base_score":2.302585092994046,"endowment":2.302585092994046,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36547048","pmcid":"PMC9777138","openalex_id":"https://openalex.org/W4311855616","authors":[],"funders":[{"funder_name":"Austrian Science Fund FWF","grant_id":"P2123333","title":null}],"total_grants":1,"fwci":0.8365,"citation_percentile":0.74631749,"influential_citations":0,"citation_trend":[{"year":2023,"count":1},{"year":2024,"count":5},{"year":2025,"count":3}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/2304-6767/10/12/232/pdf?version=1670483272","host_type":"journal"},{"url":"https://www.mdpi.com/2304-6767/10/12/232/pdf?version=1670483272","host_type":"publisher"},{"url":"https://www.mdpi.com/2304-6767/10/12/232/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/dj10120232","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36547048","host_type":"repository"},{"url":"https://doaj.org/article/e1549d770558426d84bf86da497e1807","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9777138","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC9777138","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC9777138?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Bone health and treatments","Cancer Diagnosis and Treatment","Oral and gingival health research"],"mesh_terms":[],"keywords":["Pazopanib","Medicine","Adverse effect","Renal cell carcinoma","Sunitinib","Oncology","Internal medicine","Metastatic Renal Cell Carcinoma","Angiogenesis Inhibitors","Gingival Bleeding","Jaw Osteonecrosis","Oral Side Effects"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-29T12:43:49.005392Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}